 |
1-(fluoro-18F)-3-((2-((1E,3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dien-1-yl)benzo[d]thiazol-6-yl)oxy)propan-2-ol |
|---|---|
| Trade Name | |
| Orphan Indication | Progressive supranuclear palsy |
| USA Market Approval | USA |
| USA Designation Date | 2017-11-01 00:00:00 |
| Sponsor | Aprinoia Therapeutics;17F, No. 3 Yuanqu Street;Nangang District |
